Pediatrix Medical Group, Inc. (NYSE:MD) Receives $16.10 Consensus Target Price from Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $16.10.

Several equities analysts have commented on the company. Truist Financial increased their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Mizuho raised their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Jefferies Financial Group increased their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday.

Insiders Place Their Bets

In other news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of hedge funds have recently added to or reduced their stakes in MD. Rubric Capital Management LP boosted its holdings in shares of Pediatrix Medical Group by 1.5% in the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after acquiring an additional 125,000 shares during the period. State Street Corp lifted its holdings in shares of Pediatrix Medical Group by 1.4% in the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock worth $41,038,000 after buying an additional 50,597 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Pediatrix Medical Group by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock valued at $22,452,000 after acquiring an additional 45,155 shares during the period. Dana Investment Advisors Inc. grew its stake in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares in the last quarter. Finally, Weiss Asset Management LP grew its stake in Pediatrix Medical Group by 50.5% during the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after acquiring an additional 306,143 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Trading Down 0.2 %

Shares of NYSE:MD opened at $14.17 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The company’s 50-day moving average price is $13.93 and its 200 day moving average price is $10.68. The company has a market cap of $1.22 billion, a PE ratio of -4.63, a P/E/G ratio of 2.10 and a beta of 1.57.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 earnings per share. Sell-side analysts anticipate that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.